New pill combo aims to fight stomach cancer when first treatment fails

NCT ID NCT07552402

Recruiting now Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests whether taking oral paclitaxel plus fruquintinib can help people with advanced stomach or gastroesophageal junction cancer after their first treatment stops working. About 150 adults will receive either the new drug combo or standard chemotherapy chosen by their doctor. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral paclitaxel solution plus fruquintinib
What this could lead to: If successful, this could provide a new second-line treatment option for advanced gastric cancer, potentially slowing tumor growth and improving survival.
What could go wrong: This is an early-stage trial with only 150 participants, so results may not apply to all patients. The combination may cause side effects like toxicity, and it may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Baotou Cancer Hospital
RECRUITING

Baotou, Inner Mongolia, China
The Affiliated Hospital of Harbin Medical University
RECRUITING

Harbin, Heilongjiang, China
The Second Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.